ERBB3 and breast cancer: Here, we take advantage of the same cell models to determine if the trastuzumab-resistant breast cancer cells become refractory to lapatinib, and to explore whether erbB3- and IGF-1R-initiated signaling pathways differentially modulate lapatinib sensitivity.